Public Health Laboratory Testing Sample Clauses

Public Health Laboratory Testing. For a complete list of all 15 public health preparedness capabilities, visit ▇▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/cpr/readiness/capabilities.htm.
View SourceView Similar (3)
Public Health Laboratory Testing. Introduction
View SourceView Similar (2)
Public Health Laboratory Testing. Introduction Although not encompassing all aspects of laboratory functions, the intent of these performance measures is to serve as a foundation for describing and assessing laboratory capabilities among PHEP-funded laboratories.
View Source
Public Health Laboratory Testing. Work for this capability will be addressed in future contract years.
View Source
Public Health Laboratory Testing. Public health agencies must ensure their jurisdictions have the ability to quickly, safely, and accurately perform laboratory testing on suspected Ebola virus specimens as well as manage any surges of specimen testing and analysis. Laboratory testing must be conducted according to CDC’s Interim Guidance for Specimen Collection, Transport, Testing, and Submission for Persons Under Investigation for Ebola Virus Disease in the United States or other updated guidance from CDC. Awardees should support and advance Laboratory Response Network (LRN) activities including: • 24/7/365 availability of reverse transcription-polymerase chain reaction (RT-PCR) testing for EVD in designated LRN facilities, according to the methods and reporting requirements promulgated by CDC or LRN. • Appropriate collection and handling of hospital and other clinical laboratory specimens that require EVD testing and shipping to LRN or CDC laboratories designated for testing. • Acquiring and maintaining at least two (2) LRN-approved RT-PCR instruments that will replace the existing standard LRN instrument (ABI 7500 DX). Awardees should develop a sustainability plan for equipment purchased for this activity. • Adherence to required infection control precautions and practices, specifically for handling blood-borne pathogens, when collecting and handling specimens. Support provision of EVD training, including but not limited to laboratory safety and diagnostic methods. • Rapidly reporting Ebola test results between the laboratory, the public health department, and healthcare facilities to support public health investigations.
View Source
Public Health Laboratory Testing. Community Preparedness For a complete list of all 15 public health preparedness capabilities, visit ▇▇▇.▇▇▇.▇▇▇/▇▇▇▇/▇▇▇▇▇▇▇▇▇/▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. KEY STRENGTH KEY CHALLENGE Trained personnel to plan and participate in Full Scale Exercises Lack of documentation of call-down drills Households included children 39% Respondents who know they are pregnant 4% Respondents 65 or older 21% Respondents who reported having diabetes 10% Respondents who reported a condition that limits activities 21% Respondents who reported a health problem that required the use of specialized equipment 9% PHEP funds support staff who have expertise in many different PHEP-Funded Staff areas. CDC Field Staff 8 Educators 3 Epidemiologists 7 Health Professionals — Laboratorians 9 Other Staff 14 PHEP Program–Key Performance Measure Results Emergency Operations Coordination 2014 2015 2016 Laboratory Response Network biological (LRN-B) and PulseNet labs rapidly identify and notify CDC of potential biological health threats to minimize disease outbreaks. CDC manages the LRN-B, a group of public health labs with testing capabilities to detect and confirm biological health threats. CDC also manages PulseNet, a national network of labs that analyzes and connects foodborne illness cases together to identify outbreak sources. Current number of LRN-B public health labs: 1 Number of minutes for public health staff with incident management lead roles to report for immediate duty
View Source

Related to Public Health Laboratory Testing

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act. (B) All classes covered by this Agreement are designated special risk classes for drug testing purposes. Special risk means employees who are required as a condition of employment to be certified under Chapter 633 or Chapter 943, F.S. (C) An employee shall have the right to grieve any disciplinary action taken under section 112.0455, the Drug-Free Workplace Act, subject to the limitations on the grievability of disciplinary actions in Article 10. If an employee is not disciplined but is denied a demotion, reassignment, or promotion as a result of a positive confirmed drug test, the employee shall have the right to grieve such action in accordance with Article 6.

  • Substance Abuse Testing The Parties agree that it is in the best interest of all concerned to promote a safe working environment. The Union has no objection to pre-employment substance abuse testing when required by the Employer and further, the Union has no objection to voluntary substance abuse testing to qualify for employment on projects when required by a project owner. The cost and scheduling of such testing shall be paid for and arranged by the Employer. The Union agrees to reimburse the Employer for any failed pre-access Alcohol and Drug test costs.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.